CAM
SCMP

Capstone Asset Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Capstone Asset Management’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$130K Buy
12,360
+260
+2% +$2.65K ﹤0.01% 1562
2017
Q1 		$133K Buy
+12,100
New +$140K ﹤0.01% 1578

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capstone Asset Management's SCMP Position: Q2 2017 in Review

Capstone Asset Management increased its Sucampo Pharmaceuticals, Inc. (SCMP) stake by 2.1% in Q2 2017, buying an estimated $2.65K and bringing the position to 12,360 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #1562.

Capstone Asset Management first reported a position in SCMP in Q1 2017 and has held it in 2 quarters since. The position peaked at $133K in Q1 2017. 167 funds tracked by Wall St. Rank hold SCMP as of Q2 2017.

  • Capstone Asset Management held 12,360 shares of Sucampo Pharmaceuticals, Inc. worth $130K as of Q2 2017.
  • Capstone Asset Management bought 260 Sucampo Pharmaceuticals, Inc. shares in Q2 2017, an estimated $2.65K.
  • Sucampo Pharmaceuticals, Inc. made up ﹤0.01% of Capstone Asset Management's portfolio in Q2 2017, its #1562 holding.
  • Capstone Asset Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2017 and has held it in 2 quarters since.
  • Capstone Asset Management's Sucampo Pharmaceuticals, Inc. position peaked at $133K in Q1 2017.
  • 167 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.